Combined treatment of cisplatin and anti-CD137 or anti-PD-1 monoclonal antibodies (mAbs) also creates a synergistic therapeutic effect in an ID8 mouse ovarian cancer model [39]. This evidence concerns the gene TNFRSF9 and ovarian carcinoma.